WallStSmart

Bausch + Lomb Corp (BLCO)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 6% more annual revenue ($5.65B vs $5.32B). RMD leads profitability with a 27.0% profit margin vs -3.2%. BLCO appears more attractively valued with a PEG of 0.89. RMD earns a higher WallStSmart Score of 67/100 (B-).

BLCO

Hold

45

out of 100

Grade: D+

Growth: 5.3Profit: 3.5Value: 5.0Quality: 4.5
Piotroski: 2/9Altman Z: 0.91

RMD

Strong Buy

67

out of 100

Grade: B-

Growth: 6.0Profit: 9.0Value: 4.7Quality: 9.0
Piotroski: 5/9Altman Z: 4.53
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BLCOSignificantly Overvalued (-76.3%)

Margin of Safety

-76.3%

Fair Value

$9.66

Current Price

$16.80

$7.14 premium

UndervaluedFair: $9.66Overvalued
RMDSignificantly Overvalued (-24.1%)

Margin of Safety

-24.1%

Fair Value

$209.18

Current Price

$223.61

$14.43 premium

UndervaluedFair: $209.18Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BLCO2 strengths · Avg: 9.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

PEG RatioValuation
0.898/10

Growing faster than its price suggests

RMD6 strengths · Avg: 9.2/10
Operating MarginProfitability
30.9%10/10

Strong operational efficiency at 30.9%

Altman Z-ScoreHealth
4.5310/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
23.1%9/10

Every $100 of equity generates 23 in profit

Profit MarginProfitability
27.0%9/10

Keeps 27 of every $100 in revenue as profit

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

Free Cash FlowQuality
$1.65B8/10

Generating 1.6B in free cash flow

Areas to Watch

BLCO4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-3.4%2/10

ROE of -3.4% — below average capital efficiency

EPS GrowthGrowth
-88.6%2/10

Earnings declined 88.6%

Altman Z-ScoreHealth
0.912/10

Distress zone — elevated risk

RMD1 concerns · Avg: 4.0/10
EPS GrowthGrowth
2.4%4/10

2.4% earnings growth

Comparative Analysis Report

WallStSmart Research

Bull Case : BLCO

The strongest argument for BLCO centers on Price/Book, PEG Ratio. PEG of 0.89 suggests the stock is reasonably priced for its growth.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.0% and operating margin at 30.9%. PEG of 1.31 suggests the stock is reasonably priced for its growth.

Bear Case : BLCO

The primary concerns for BLCO are Piotroski F-Score, Return on Equity, EPS Growth.

Bear Case : RMD

The primary concerns for RMD are EPS Growth.

Key Dynamics to Monitor

BLCO profiles as a turnaround stock while RMD is a mature play — different risk/reward profiles.

RMD carries more volatility with a beta of 0.77 — expect wider price swings.

BLCO is growing revenue faster at 9.1% — sustainability is the question.

RMD generates stronger free cash flow (1.6B), providing more financial flexibility.

Bottom Line

RMD scores higher overall (67/100 vs 45/100), backed by strong 27.0% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bausch + Lomb Corp

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Bausch Lomb Corporation is an eye health company in Canada and internationally. The company is headquartered in Vaughan, Canada.

Visit Website →

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?